Cargando…
Outcome of patient with high-risk chronic myelomonocytic leukemia, treated with decitabine prior to transformation to acute myeloid leukemia: A case report
The present study describes a patient with high-risk chronic myelomonocytic leukemia (CMML), for whom decitabine therapy achieved partial remission, prior to a sudden transformation to acute myeloid leukemia (AML) and an inferior outcome. The 53-year-old male reported easily bruising for 5 months. E...
Autores principales: | Liu, Huan, Cheng, Juan, Zhao, Long, Xu, Qian, Xue, Mingming, Zhang, Shuling, Liu, Bei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5921036/ https://www.ncbi.nlm.nih.gov/pubmed/29731877 http://dx.doi.org/10.3892/ol.2018.8236 |
Ejemplares similares
-
Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada
por: Yun, John Paul, et al.
Publicado: (2023) -
Reversible cardiomyopathy in a patient with chronic myelomonocytic leukemia treated with decitabine/cedazuridine: a case report
por: Sheel, Ankur, et al.
Publicado: (2023) -
A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia
por: Santini, V, et al.
Publicado: (2018) -
Successful management of acute myeloid leukemia transformed from chronic myelomonocytic leukemia in the elderly by a combination regimen of decitabine and cytarabine, aclarubicin and granulocyte colony-stimulating factor: A case report
por: DENG, QI, et al.
Publicado: (2015) -
Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia
por: Li, Bing, et al.
Publicado: (2014)